Advancing Neurology and Neuro-Oncology Symposium

This symposium will provide a comprehensive, case-based update in neuro-oncology, featuring expert-led lectures and panel discussions with leaders in the field. The program will open with a historical perspective on the Department of Neurology at Memorial Sloan Kettering Cancer Center, followed by focused sessions on hematolymphoid malignancies involving the central nervous system, neurologic complications of cancer and its therapies, CNS metastases, and glioma.

Through multidisciplinary perspectives, clinical insights, and the latest research updates, this symposium is designed to enhance clinicians’ understanding of complex neurologic conditions in oncology and support evidence-based, collaborative patient care. A complete program agenda and brochure will be available soon.

Dr. Lisa M. DeAngelis dedicated nearly four decades to Memorial Sloan Kettering Cancer Center, beginning as a neuro-oncology fellow and ultimately serving as Chair of the Department of Neurology. She also held key institutional leadership roles, including Physician-in-Chief and Chief Physician Executive.

Target Audience: This symposium is intended for neurologists, neuro-oncologists, medical oncologists, neurosurgeons, radiation oncologists, hematologists, oncology trainees, advanced practice providers, and other healthcare professionals involved in the care of patients with neurologic complications of cancer or primary and metastatic tumors of the central nervous system. Registration is complimentary for all participants.

Location: This symposium will be held at the David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center (530 East 74th Street), in the 6th Floor East River Room.

1. Review the historical contributions and evolution of neuro-oncology at MSK and its impact on the field of cancer neurology.
2. Discuss current diagnostic approaches and emerging therapies, including advances in targeted therapy and immunotherapy.
3. Describe neurologic complications associated with cancer and cancer therapies, including immunotherapy-related neurotoxicity, tumor-related epilepsy, and stroke in patients with malignancy.
4. Discuss contemporary strategies for the classification and treatment of primary and metastatic CNS tumors, as well as innovations in neuro-oncology research and training.

At this time, due to space limitations, this symposium is by invitation only. Please register only if you have received an invitation to attend.

If you have been invited, kindly select the Registration tab above and complete the form to confirm your attendance. If you have any questions, or if you are registered and unable to attend, please email, [email protected] for assistance.

For details on our cancellation terms, please review our Cancellation Policy.

"Industry professionals" are welcome to attend Continuing Medical Education events at MSK for their own educational purposes. View our Registration Policy for Industry Professionals for more information.

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

MSK Symposium Director 

Ingo K. Mellinghoff, MD, FACP
Chair, Department of Neurology
Evnin Family Chair in Neuro-Oncology

Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer Center adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.